Navigation Links
Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
Date:8/17/2010

VANCOUVER, Canada, Aug. 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

XEN402 has been developed by Xenon as a topical ointment formulation and recently concluded a 21-day cumulative dose safety tolerability phase 1 study in normal human volunteers.  The product was well tolerated and achieved good drug concentrations in the skin.  Topical XEN402 is being developed by Xenon for painful neuropathic disorders such as PHN and targets the sodium channel sub-type Nav1.7. This target is highly expressed in sensory nerve endings and its expression has been shown to be up-regulated in chronic painful conditions such as PHN.

"This is an important step forward in the development of topical XEN402," said Xenon President & CEO, Dr. Simon Pimstone.  "This is a truly unique product built on our genetic studies that showed Nav1.7 deficient humans are completely unable to feel pain. By treating pain locally at its source through Nav1.7 block, topical XEN402 could be a very effective and safe treatment option. Our pre-clinical data show excellent efficacy with topical XEN402 in multiple inflammatory and neuropathic pain models when compared to other topical agents and additive effects to existing oral pain treatments.  We are excited by these findings as the product could eventually treat multiple chronic painful conditions.  This progress signifies another example of Xenon transitioning its target discovery engine to human proof-of-concept trials."

Xenon's VP, Clinical Development, Dr. Paul Goldberg referred to topical XEN402 as a "potentially transformative therapy as leading agents have significant side effects and often leave many patients still in pain.  As such there is a large unmet medical need for a novel analgesic that is both effective and safe. We see topical XEN402 being used both as a monotherapy and as an adjuvant agent as well," he added.

Xenon expects to conclude the phase 2 trial in Q1, 2011 with top-line data available in Q2, 2011.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
2. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
3. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
4. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
9. Angiotech Pharmaceuticals Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ: ... Mr John O,Connor , and new Deputy Chairman, Mr ... Garner , has also been formally appointed to the Board ... Iain Ross , will resume his role on the Board ... has also been formally appointed to the Board as an ...
(Date:2/4/2016)... 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that Edward Lanphier , Sangamo,s president and chief ... of Sangamo,s ZFP Therapeutic ® development programs and ... pm ET on Thursday, February 11, 2016, at the ... The conference is being held in New ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, ... various medical institutions attended a ceremony in late 2015 ... personalized cell therapy in 2016. --> ... Clinical Translation Platform for Personalized Cell Therapy" was hosted ... Cell Production Center, both subsidiaries of Beike Biotechnology Co., ...
(Date:2/4/2016)... 4, 2016 --> ... company is pleased to provide the following update on recent ... Over the last 3 months we have significantly increased our ... exceeding $1,000,000. As a result, we have positioned ourselves to ... license agreement and expect that development to continue on schedule. ...
Breaking Biology Technology:
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
(Date:1/27/2016)... 27, 2016  Rite Track, Inc. a leading semiconductor ... West Chester, Ohio announced today the acquisition ... based in Austin, Texas , will ... provide modifications, installations and technical support offerings for TEL ... PLUS, commented, "PLUS has provided world class service including ...
Breaking Biology News(10 mins):